Preparation and cytotoxicity effect of anti-hepatocellular carcinoma SCFV immunoliposome on hepatocarcinoma cell in Vitro

European Journal of Inflammation

Volumn 8, Issue 2, 2010, Pages 75-82

  Zhang, Gui Hong ^a   Liu, Y F ^a   Hu, H Y ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cytotoxicity; Immunoliposome; Immunotoxin; PE38

Indexed keywords

CHOLESTEROL; IMMUNOLIPOSOME; IMMUNOTOXIN; LIPOSOME; MACROGOL; PE 38; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA;

EID: 77957906369     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1000800204     Document Type: Article

References (33)

1. Zhang XP, Bing D, Qian M. Application of recombinant immunotoxin PE in tumour targeted therapy. Immunol J 2004; 20:52-55.
2. Xi YZ, Zheng LY, Sun YY. Molecular design and construction of L1-6D24-PE40kDEL, a novel recombinant in terleukin6-pseudomonas exotoxin fusion protein, having targeted cytotoxity for leukemias expressing interleukin6 receptors. Hum Immunol 2003; 64:247-8.
3. Bang S, Nanata S, Onada M, Pincus SH, Marcotte TK, Forsyth BM. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005; 11:1545-50. (Pubitemid 40315239)
4. Madhu SS, Narayanasamy K, Mandip S. Conjugation of anti-My9 antibody to stealth monensin liposomes and the effect of conjugated liposomes on the cytotoxicity of immunotoxin. J Control Release 2001; 76:285-95.
5. Benbrook DM. An ELISA method for detection of human antibodies to an immunotoxin. Jo Pharmacol Toxicol Meth 2002; 47:169-175. (Pubitemid 36287357)
6. Wang HJ, Dai JX, Li BH, Fan KX, Peng L, Zhang DP, Cao ZG, Qian WZ, Wang H, Zhao J, Guo YJ. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A. Protein Expr Purif 2008; 58:140-7.
7. Martin K, Rainer, Hauke L. Design of a modular-immunotoxin connected by polyionic adapter peptides. J Molec Biol 2003; 327:445-52.
8. He D, Yang H, Lin Q, Huang H. Arg9-peptide facilitates the internalization of an anti-CEA immunotoxin and potentiates its specific cytotoxicity to target cells. Int J of Biochem Cell Biol 2005; 37:192-205. (Pubitemid 39286035)
9. Ki-Uk K, Daniel A, Vallera N, Kwan H, Stephen R, Spellman H, Walter C, Walter A. Immunotoxin therapy for primary malignant brain tumors. Int Congress Series 2002; 1247:185-97.
10. Nielsen UB, Kirpotin DB, Pickering EM. Therapeutic efficacy of anti-ErbB2 immnoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002; 1591:109-18. (Pubitemid 35232074)
11. Park JW, Hong,K, Kirpotin DB, Colbern G, Shalaby MR, Baselga Y. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.Clin. Cancer Res 2002; 8:1172-81. (Pubitemid 35177372)
12. Maruy K, Holmberg E, Kennel SJ. Characterization of in vivo immunoliposome targeting to pulmonary endothelium. J Pharm Sci 1990; 79:978-84. (Pubitemid 20376189)
13. Onda M, Wang QC, Guo HF. In Vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res 2004; 64:1419-24. (Pubitemid 38235611)
14. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm 2007; 338:317-26. (Pubitemid 46777245)
15. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Tumor targeting using anti-her2 immunoliposomes. J Control Release 2001; 74:95-113. (Pubitemid 32727613)
16. Yuan QA, Yu WY. Gene construction and expression in colibacillus of hepatoma specific mouse and humanized single-chain antibody. J Bioeng 2000; 16:86-90.
17. Sun ZW, Liu YF. The initial empirical study of fusing and targeting of single-chain antibody against hepatoma and TNFa. J Cells Molec Immunol 2001; 17:69-72.
18. Zhao J, Sun ZW, Liu YF. Construction expression and function test of the fusion gene of stabilized disulfide bond single-chain antibody against hepatoma and PE38. Cell Mol Immunol 2003; 19:585-7.
19. Lu J, Jeon E, Lee BS, Onyuksel H, Wang ZJ. Targeted drug delivery crossing cytoplasmic membranes of intended cells via ligand-grafted sterically stabilized liposomes. J Control Release 2006; 110:505-13. (Pubitemid 43163440)
20. Yang T, Choi MK, Cui FD, Weis W, Biburger M, Muller T. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J Control Release 2007; 120:169-77. (Pubitemid 47061489)
21. Kreitman RJ, Wilson WH, Bergeron K, Nagata K, Komatsu T. Efficacy of the anti-CD22 recombinnant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345:241-7. (Pubitemid 32695063)
22. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC. Cytotoxic activity of disulfide stabilized recombinant immunotoxin RFB4(dsFv) PE38(BL22) toward fresh malignant cells from patients with B cell leukemias. Clin Cancer Res 2000; 6:1476-87. (Pubitemid 30226237)
23. Feng B, Tomizawa K, Michiue H. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 2009; 30:1746-55.
24. Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004; 31:196-205. (Pubitemid 40023249)
25. Knechtle SJ. Treatment with immunotoxin. Philos Trans R SOc Lond B Biol Sci 2001; 356:681-89. (Pubitemid 32575700)
26. Khaw B, Jose Da, William C, Hartner W. Cytoskeletal-antigen specific immunoliposome-targeted in vivo preservation of myocardial viability. J Control Release 2007; 120:35-40. (Pubitemid 46876742)
27. Hu HY, Cheng DW, Liu YF, Qiao MX, Zhao XL. Preparation and selectivity to tumor cells in vitro of bee venom polypeptide sterically stabilized immunoliposome. Acta Pharmaceutica Sinea 2007; 42:1201-5.
28. Hu HY, Cheng DW, Liu YF, Deng YH, Yang SJ, Qiao MX, Zhao J, Zhao XL. target ability and therapy efficacy of immunoliposomes using a humanized anti-hepatoma disulfide-stabilized Fv fragment on tumor cells. J Pharm Sci 2006; 95:192-9.
29. Hu HY, Cheng DW, Li YF Zhang XG. Effect of growth inhibition and apoptosis induction of polypepetides in bee venom on human hepatoman cell line SMMC-7721 in vitro and Balb/c nude mice in vivo. J Pharm Pharmaco 2006; 58:83-9.
30. Hou X, Zhang YF, Xie SS. Target ability of the third generation carried drugs immunoliposomes in vitro and in vivo. Acta Pharmaceutica Sinea 2001; 36:539-42.
31. Zhang YF, Xie SH, Hou XP. Preparation and distribution of active carboxyl terminal and long circulation liposomes. Acta Pharmaceutica Sinea 2000; 35:854-9.
32. Keppler A, Kreitman RJ, Pastan G. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int J Cancer 2000; 87:86-94. (Pubitemid 30368420)
33. Onda M, Nagata S, Tsutsumi Y. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res 2001; 61:5070-7. (Pubitemid 32681537)